Elobixibat and its potential role in chronic idiopathic constipation
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Chronic idiopathic constipation is highly prevalent among adults. Bile acids (BAs) and the enterohepatic BA circulation modulate colonic secretion and motility that affect transit. BAs in the colon have a dual action as osmotic and stimulant agents. Newer agents, such as elobixibat (A3309), an inhibitor of the ileal BA transporter, have the potential to improve significantly the management of chronic constipation, with minimal adverse effects. Elobixibat modulates the enterohepatic BA circulation, enhancing the delivery of BAs to the colon where they induce secretory and motor effects. Secondary effects of the inhibition of BA absorption are reduced activation of the farnesoid X receptor, decreased secretion of fibroblast growth factor-19 into the portal circulation, and increased BA synthesis. This review focuses on the role of BAs, the enterohepatic BA circulation, and an ileal BA transporter inhibitor (elobixibat) in chronic constipation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Secretory mechanisms are common therapeutic targets94, 95 of medications used to treat FGIDs.”
From The gut Microbiome in adult and pediatric functional gastrointestinal disorders (2019) · cites this paper as [94]
Citations
Cites
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
American Gastroenterological Association Technical Review on Constipation
Bharucha, A. E., Pemberton, J. H., & Locke, G. R. (2013) · Gastroenterology · doi:10.1053/j.gastro.2012.10.028 · Cited by 909
Lembo, A., & Camilleri, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020995 · Cited by 692
Self-citationChronic constipation: a survey of the patient perspective
JOHANSON, J. F., & KRALSTEIN, J. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03238.x · Cited by 617 · cited 2×
“…Clinic, Rochester, MN, USA 168 http://tag.sagepub.com with the current treatment options prior to the approval of linaclotide, lubiprostone, and prucalopride [Johanson and Kralstein, 2007], including patients participating in phase III clinical trials of new treatments for CC [e.g. Camilleri et al.”
MethodColonic Secretion of Water and Electrolytes Induced by Bile Acids: Perfusion Studies in Man
Mekhjian, H. S., Phillips, S. F., & Hofmann, A. F. (1971) · Journal of Clinical Investigation · doi:10.1172/jci106644 · Cited by 584
A placebo-controlled trial of prucalopride for severe chronic constipation
Camilleri, M., Kerstens, R., Rykx, A., & Vandeplassche, L. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800670 · Cited by 576
Self-citationAmerican Gastroenterological Association Medical Position Statement on Constipation
Bharucha, A. E., Dorn, S. D., Lembo, A., & Pressman, A. (2013) · Gastroenterology · doi:10.1053/j.gastro.2012.10.029 · Cited by 521
DROSSMAN, D. A., CHEY, W. D., JOHANSON, J. F., FASS, R., SCOTT, C., PANAS, R., & UENO, R. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03881.x · Cited by 399
Two randomized trials of linaclotide for chronic constipation
Lembo, A. J., Schneier, H. A., Shiff, S. J., Kurtz, C. B., MacDougall, J. E., Jia, X. D., Shao, J. Z., Lavins, B. J., Currie, M. G., Fitch, D. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010863 · Cited by 373
Alemi, F., Poole, D. P., Chiu, J., Schoonjans, K., Cattaruzza, F., Grider, J. R., Bunnett, N. W., & Corvera, C. U. (2013) · Gastroenterology · doi:10.1053/j.gastro.2012.09.055 · Cited by 362 · cited 1×
“Expression and function of GPBAR1 are involved in the prokinetic effects of BAs [Alemi et al. 2013]; genetic variation in GPBAR1 was associated with acceleration of small intestinal and colonic transit [Camilleri et al.”
Background
Research works printed but not linked: 1
- Gillberg P., Dahlstrom M., Starke I., Ostlund-Lindqvist A. (2010) The IBAT inhibition by A3309 a potential mechanism for the treatment of constipation. Gastroenterol Clin North Am 138: S224.
Cited by
Management of functional constipation in children and adults
Vriesman, M. H., Koppen, I. J. N., Camilleri, M., Di Lorenzo, C., & Benninga, M. A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0222-y · Cited by 457
Self-citationGuts and Gall: Bile Acids in Regulation of Intestinal Epithelial Function in Health and Disease
Hegyi, P., Maléth, J., Walters, J. R., Hofmann, A. F., & Keely, S. J. (2018) · Physiological Reviews · doi:10.1152/physrev.00054.2017 · Cited by 269
“An alternative approach currently under investigation for increasing colonic bile acids in treatment of constipation is the use of ASBT inhibitors, such as elobixibat, that prevent bile acid absorption in the terminal ileum (2) (see sect.”
BackgroundBlack, C. J., & Ford, A. C. (2018) · Medical Journal of Australia · doi:10.5694/mja18.00241 · Cited by 228
Nakajima, A., Seki, M., Taniguchi, S., Ohta, A., Gillberg, P.-G., Mattsson, J. P., & Camilleri, M. (2018) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(18)30123-7 · Cited by 169
Self-citationThe gut Microbiome in adult and pediatric functional gastrointestinal disorders
Shin, A., Preidis, G. A., Shulman, R., & Kashyap, P. C. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.08.054 · Cited by 163
Metadata
- Authors
- Acosta, A., & Camilleri, M.
- Affiliations
- Mayo Clinic (US)
- Venue
- Therapeutic Advances in Gastroenterology
- Publisher
- SAGE Publications
- Published
- 2014-03-27
- Volume
- 7
- Issue
- 4
- Pages
- 167-175
- ISSN
- 1756-283X (ISSN-L)
- 1756-2848
- PMC
- PMC4107709
- OpenAlex
- W2057872155
- Cited by
- 91
- References
- 45
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 7 · 2023: 5 · 2022: 12 · 2021: 6 · 2020: 13 · 2019: 7 · 2018: 13 · 2017: 5 · 2016: 6 · 2015: 5 · 2014: 1
- FWCI
- 0.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Therapeutic Advances in Gastroenterology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK092179, T32DK007198)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Keywords
- elobixibat, chronic idiopathic constipation, bile acids, enterohepatic circulation, farnesoid X receptor, FGF19, colonic secretion, colonic motility, bile acid synthesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Elobixibat and its potential role in chronic idiopathic constipation. https://app.cochat.ai/papers/10.1177/1756283x14528269
- The paper
- Acosta, A., & Camilleri, M. (2014). Elobixibat and its potential role in chronic idiopathic constipation. Therapeutic Advances in Gastroenterology. https://doi.org/10.1177/1756283x14528269
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.